and evaluated in two other studies, one retrospective (225 patients with long term follow up)2 and one prospective (195 patients, with short term follow up3 and subsequent longer term follow up).4 In these studies a discrepancy between lymph node response (as negative or positive) and MPI (with 0 60 as the cut off) existed in 14-25% of all cases and the actual outcome of the patients was more in agreement with the MPI than with the lymph node classification. Other groups also found that the MPI offers exceedingly good prognostic value (Dr Collan, Finland; Dr Bathal, Melbourne; Dr Peterse, EORTC Amsterdam, personal communications).
In the meantime, we had the opportunity to discuss their results with Laroye and his colleagues. Their survival data indicate that: (a) lymph node response survival curves are similar to those of our previously published material.' This eliminates the possibility of differences in the accuracy of axillary lymph node sampling between our material; (b) that their patients with an MPI of more than 0 60 fared better than their lymph node positive patients.
There is only one explanation for this: that large tumour size and high mitotic rate in their material were associated with a better prognosis than cases without these features. This does not agree with all the reported findings of the past 65 years, and it seems that their findings should be interpreted very carefully.
We do not agree with their statement that a significant arithmetical error exists in our published paper,2 and we also believe that our original conclusions are not correctly interpreted. We literally said: "in agreement with the results of the previous retrospective study, the prospective use of the index had the strongest predictive prognostic value, followed by the mitotic activity index. Statistical analysis showed that the actual prognoses of 43 of the 195 (22%) patients were more accurately determined by the prognostic index rather than by using the presence of 
the lymph node metastases as the classifying variable". This statement is true, because as mentioned in our article, the recurrence-free survival curves and Mantel-Cox values of the patients who were lymph node negative and had an MPI of > 0 60 were no different from those who were lymph node positive. In fact, the survival curves showed complete overlap; the same was found for those who were lymph node positive with an MPI of less than 0-60 and those who were lymph node negative (figure).
To suggest that of the 13 patients with an MPI of more than 0-60 and without recurrence are "false positives", as Dr Laroye has done with our material, is a "fixed endpoint approach". This is absolutely wrong as in this prospective study the 
